ClinicalTrials.gg
TerminatedNCT04634799Updated Sep 25, 2026Results posted

Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

A Phase 1/2 interventional study of TM5614 and Placebo in Covid19, sponsored by Northwestern University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Northwestern University · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Enrollment challenges due to decline in COVID
Updated Sep 25, 2026Now TerminatedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
1,156th of 1,322
9 · median 92
Started
2021
with 503 others
Phase 1/2
62 of 1,860
4 open now
Registered
806th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 1,156th largest by enrollment of the 1,322 interventional ones that give a count, is one of 504 that started in 2021, is one of 62 in phase 1/2, and was the 806th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This is a single-center, randomized double blind placebo controlled trial to evaluate the efficacy and safety of novel PAI-1 inhibitor (TM5614) for high-risk patients hospitalized with severe COVID-19 at Northwestern Memorial Hospital. The patients will be randomized in a 1:1 ratio to receive standard of care plus TM5614 or standard of care plus placebo.

Read the detailed description

This project will evaluate the efficacy and safety of a novel small molecule therapy targeting PAI-1 (TM5614) for patients with severe COVID-19. This is a randomized (1:1), double-blinded trial that will enroll adult patients (> 65 years OR \<65 years with at least one major cardiometabolic comorbidity [diabetes, hypertension, or cardiovascular disease]) with COVID-19 requiring supplemental oxygen. The study intervention will be a small molecule inhibitor of PAI-1, TM5614, up to 180 mg, compared to matching placebo for up to 7 days.

Research blood samples for PAI-1 and C-reactive protein (CRP) will be collected at time of enrollment, 48 hours after 1st dose of medication and at day 7 or discharge, whichever comes first.

These objectives will allow for the planning of subsequent phase 3 study, and strengthen implementation of a multi-center randomized trial should this study confirm safety, and suggest efficacy of therapy.

03

Conditions studied

  • Covid19

Browse trials for

Keywords

  • PAI-1
  • TM5614
  • Plasminogen Activator Inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥65 years old or \< 65 years old AND at least one major cardiometabolic comorbidity (diabetes, hypertension, or cardiovascular disease)
  2. Established diagnosis of COVID-19 as evidenced by a positive nasopharyngeal or bronchoalveolar lavage viral PCR for SARS-CoV2
  3. Requiring supplemental oxygen

Exclusion criteria

Exclusion Criteria:

  1. Age \<18 years old
  2. Pregnancy or breast-feeding
  3. Known to tissue plasminogen activator (tPA), including

    1. Active internal bleeding
    2. History of cerebrovascular accident
    3. Recent intracranial or intraspinal surgery or trauma
    4. Intracranial neoplasm, arteriovenous malformation or aneurysm
    5. Known bleeding diathesis
    6. Severe uncontrolled hypertension (SBP>200 persistently >12 hours)
  4. Currently receiving therapeutic dose anticoagulation (specifically will exclude those with potential drug-drug interaction such as heparin, apixaban, warfarin)
  5. \<50,000
  6. Hematocrit \<30%
  7. Not hemodynamically stable in the preceding 4 hours (symptomatic hypotension or systolic BP \<95 mmHg at 2 out of 3 measurements)
  8. Concomitant illness, physical impairment or mental condition which in the opinion of the study team / primary care physician could interfere with the conduct of the study including outcome assessment
  9. Other patient characteristics (not thought to be related to COVID-19) that portend a very poor prognosis (e.g., severe liver failure, )
  10. Participation in a concurrent interventional medical investigation or pharmacologic clinical trial. Patients in observational, natural history or epidemiological studies not involving an intervention are eligible.
  11. Participant's responsible attending physician believes it is not appropriate for participant to participate in the study.
  12. Inability or unwillingness to provide written
  13. Involvement in the planning and/or conduct of the study
  14. Previous randomization in the present study
  15. Unable to complete study procedures.
  16. Patients with active venothromboembolic disease
  17. Patients who are receiving other agents for COVID-19.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
9 participants (actual)

Study arms

  • Active comparator
    TM5614

    TM5614 30 mg tablets. 6 tablets (180 mg) taken by mouth, once daily for up to 7 days

    Drug: TM5614

  • Placebo comparator
    Placebo

    Placebo tablets. 6 tablets taken by mouth, once daily for up to 7 days

    Other: Placebo

Interventions

  • DrugTM5614

    TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.

    Also known as: Plasminogen activator inhibitor-1 (PAI-1)

  • OtherPlacebo

    Matching placebo will be provided and participants will take 6 tablets in the evening for up to 7 days.

    Also known as: TM5614 Placebo

06

What researchers measure

Primary outcomes

  1. Clinical Improvement

    Change of at least 2 points in the NIAID-defined ordinal scale (higher scores indicate improved outcome),: 1. Death 2. Hospitalized, receiving invasive mechanical ventilation or ECMO 3. Hospitalized, receiving noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring low-flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen but receiving ongoing medical care (related or not related to Covid-19) 6. Hospitalized, requiring neither supplemental oxygen nor ongoing medical care (other than that specified in the protocol) 7. Not hospitalized

    Time frame: 7 Days

Secondary outcomes

  1. Sequential Organ Failure Assessment (SOFA) Score Change

    Change in degree of organ dysfunction as defined by the Sequential Organ Failure Assessment (SOFA) Score. The SOFA score ranges from 0 to 24 (higher scores indicate more severe organ failure), with 0 to 4 points assigned for each of 6 organ dysfunctions (ie, central nervous system, cardiovascular, respiratory, renal, coagulation, and liver).

    Time frame: 7 Days

  2. PAI-1 Levels

    Change in circulating PAI-1 Levels (ng/mL) at discharge from baseline

    Time frame: 48 hours

07

Results

Posted Sep 25, 2026
Limitations and caveats
Study was terminated early.

Participant flow

Participant flow — Overall Study
MilestoneTM5614Placebo
Started44
Completed44
Not completed00

Outcome measures

PrimaryClinical Improvement

Change of at least 2 points in the NIAID-defined ordinal scale (higher scores indicate improved outcome),: 1. Death 2. Hospitalized, receiving invasive mechanical ventilation or ECMO 3. Hospitalized, receiving noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring low-flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen but receiving ongoing medical care (related or not related to Covid-19) 6. Hospitalized, requiring neither supplemental oxygen nor ongoing medical care (other than that specified in the protocol) 7. Not hospitalized

Time frame:
7 Days
Reported as:
Number · Participants
Clinical Improvement
ParticipantsTM5614Placebo
Clinical Improvement31
SecondarySequential Organ Failure Assessment (SOFA) Score Change

Change in degree of organ dysfunction as defined by the Sequential Organ Failure Assessment (SOFA) Score. The SOFA score ranges from 0 to 24 (higher scores indicate more severe organ failure), with 0 to 4 points assigned for each of 6 organ dysfunctions (ie, central nervous system, cardiovascular, respiratory, renal, coagulation, and liver).

Time frame:
7 Days
Reported as:
Median · Scores on a scale
Sequential Organ Failure Assessment (SOFA) Score Change
Scores on a scaleTM5614Placebo
Sequential Organ Failure Assessment (SOFA) Score Change0 (-4 to 0)0 (-1 to 4)
SecondaryPAI-1 Levels

Change in circulating PAI-1 Levels (ng/mL) at discharge from baseline

Time frame:
48 hours
Reported as:
Median · ng/mL
PAI-1 Levels
ng/mLTM5614Placebo
PAI-1 Levels12.0 (6.1 to 14.1)21.0 (19.9 to 40.9)

Adverse events

Collected over from enrollment until end of follow-up, up to 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TM56140/4 (0%)0/4 (0%)0/4 (0%)
Placebo0/4 (0%)2/4 (50%)2/4 (50%)
Most frequent serious events
Most frequent serious events
EventTM5614Placebo
HypotensionBlood and lymphatic system disorders0/41/4
HypoxemiaRespiratory, thoracic and mediastinal disorders0/41/4
Most frequent other events
Most frequent other events
EventTM5614Placebo
EpistaxisGastrointestinal disorders0/41/4
Elevated bicarbonate levelBlood and lymphatic system disorders0/41/4
LeukocytosisBlood and lymphatic system disorders0/41/4
Mechanical fallMusculoskeletal and connective tissue disorders0/41/4
BleedingBlood and lymphatic system disorders0/41/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TM5614PlaceboTotal
<=18 years000
Between 18 and 65 years347
>=65 years101
Sex: Female, Male
Sex: Female, Male(Participants)TM5614PlaceboTotal
Female325
Male123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TM5614PlaceboTotal
White123
Black011
Hispanic314
Region of Enrollment
Region of Enrollment(Participants)TM5614PlaceboTotal
United States448
PAI-1 Activity at Baseline
PAI-1 Activity at Baseline(ng/mL)TM5614PlaceboTotal
Median60.4 (26.3 to 73.2)17.7 (4.6 to 38.9)26.3 (4.6 to 73.2)
08

Study locations

1 site
  • Northwestern University
    Chicago, Illinois 60611, United States
09

References and documents

Publications

  • Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, Sharma L. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. JAMA. 2020 Mar 17;323(11):1092-1093. doi: 10.1001/jama.2020.1623. PubMed 32031568 ↗
  • Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30. PubMed 32007143 ↗
  • Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28. PubMed 32109013 ↗
  • Liu YC, Liao CH, Chang CF, Chou CC, Lin YR. A Locally Transmitted Case of SARS-CoV-2 Infection in Taiwan. N Engl J Med. 2020 Mar 12;382(11):1070-1072. doi: 10.1056/NEJMc2001573. Epub 2020 Feb 12. No abstract available. PubMed 32050059 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2021 to primary completion in May 2021, 4 months.

Results were first posted in Sep 2026, 5 years 4 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Apr 2025 → May 2021 and completion May 2025 → Aug 2021.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2020
First posted
Nov 18, 2020
StartActual
Jan 8, 2021
Primary completionActual
May 15, 2021was Apr 2025
CompletionActual
Aug 30, 2021was May 2025
Results first posted
Sep 25, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Terminated Enrollment challenges due to decline in COVID
changed Sep 25, 2026
Results
Results posted
posted Sep 25, 2026
Primary completion
Apr 23, 2025→May 15, 2021 (actual)
Sep 25, 2026
Study completion
May 30, 2025→Aug 30, 2021 (actual)
Sep 25, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedClinical improvementImprovementTime frame: 7 Days
Sep 25, 2026
Documents
Secondary outcomes
1 edited, 1 removed, 1 description edited
What changed in the outcomes
  • EditedSequential organ failure assessmentOrgan Failure Assessment (SOFA) score changeScore ChangeTime frame: 7 Days
  • RemovedVentilator free daysTime frame: 14 days
  • DescriptionPAI-1 Levels: how it is measured was reworded
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Suspended→Terminated
    Why stopped Enrollment challenges due to decline in COVID
    Results posted
    Primary completion Apr 23, 2025→May 15, 2021 (now actual)
    Study completion May 30, 2025→Aug 30, 2021 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedClinical improvementImprovementTime frame: 7 Days
    Secondary outcomes 1 edited, 1 removed, 1 description edited
    What changed in the outcomes
    • EditedSequential organ failure assessmentOrgan Failure Assessment (SOFA) score changeScore ChangeTime frame: 7 Days
    • RemovedVentilator free daysTime frame: 14 days
    • DescriptionPAI-1 Levels: how it is measured was reworded
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04634799
Responsible party
Sanjiv Shah (Director of Research, Bluhm Cardiovascular Institute, Northwestern University) — Principal investigator
First posted
Nov 18, 2020
Start date
Jan 8, 2021
Primary completion
May 15, 2021
Completion
Aug 30, 2021
Results posted
Sep 25, 2026
Last update
Sep 25, 2026

Study contacts

Sanjiv Shah, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion